{"id":"NCT00628498","sponsor":"Jazz Pharmaceuticals","briefTitle":"Defibrotide for Patients With Hepatic Veno-occlusive Disease: A Treatment IND Study","officialTitle":"Defibrotide for Patients With Hepatic Veno-occlusive Disease: A Treatment IND Study","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2007-12","primaryCompletion":"2016-07","completion":"2016-09","firstPosted":"2008-03-05","resultsPosted":"2017-11-30","lastUpdate":"2017-11-30"},"enrollment":1206,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Hepatic Veno-Occlusive Disease"],"interventions":[{"type":"DRUG","name":"Defibrotide","otherNames":[]},{"type":"DRUG","name":"Defibrotide","otherNames":[]}],"arms":[{"label":"Defibrotide","type":"EXPERIMENTAL"}],"summary":"Single arm, open-label study to provide Defibrotide to patients diagnosed with VOD. Defibrotide is no longer available though the Emergency Use IND mechanism (also known as compassionate use, or single patient named use). This protocol is the only mechanism by which Defibrotide can be made available to patients in the U.S.","primaryOutcome":{"measure":"Survival by Day+100 Post Stem Cell Transplant or Chemotherapy","timeFrame":"Day +100 from HSCT or 100 days from start of chemotherapy","effectByArm":[{"arm":"Defibrotide","deltaMin":49.9,"sd":null}],"pValues":[]},"eligibility":{"minAge":null,"sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":4},"locations":{"siteCount":125,"countries":["United States"]},"refs":{"pmids":["12393437","32950693","29767845"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":598,"n":1154},"commonTop":["Hypotension","Diarrhoea","Vomiting"]}}